China's NEO Brain Implant Moves From Trials Toward Everyday Use

Neuracle and Tsinghua University are scaling NEO, the world's first commercially approved invasive brain-computer interface, as paralyzed users move from trials to everyday assistive use.

China's NEO Brain Implant Moves From Trials Toward Everyday Use

China's first-of-its-kind brain-computer interface is graduating from clinical trials into real-world use. Neuracle Technology and Tsinghua University, co-developers of the coin-sized NEO implant, are scaling deployments after the device became the world's first invasive BCI cleared for commercial use beyond strict trial protocols.

Brain-computer interface concept illustration

A coin-sized chip on the dura, not in the cortex

Unlike systems that penetrate brain tissue, NEO sits on the dura mater, the membrane covering the brain. It records neural activity and streams it wirelessly to an external decoder that converts intent into commands for assistive devices — most notably a robotic glove that restores grasp in patients paralyzed by cervical spinal-cord injuries.

From 36 trial procedures to commercial scale

China's National Medical Products Administration cleared NEO this spring for patients aged 18 to 60 with quadriplegia following cervical SCI. The approval followed 36 procedures — four feasibility implants and 32 multicenter Good Clinical Practice studies — in which every participant reportedly recovered some grasping function. One patient, Dong Hui, was able to write his name 11 months after implantation, according to a MIT Technology Review profile this week.

A different race than Neuralink's

NEO's epidural placement is deliberately less invasive than Elon Musk's Neuralink or Synchron approaches, trading bandwidth for surgical risk. That trade-off has helped Chinese regulators move first on a commercial label, while U.S. systems are still confined to trial cohorts. The rollout intersects with a wider neurotech build-out in China backed by hospitals, regional governments and — unusually for an early medical device — substantial venture capital, mirroring the policy push behind Asian humanoid deployments.

What's next for Neuracle

The company is preparing follow-on indications, including communication and computer control for ALS patients, and is pursuing trials outside China. The deployment also widens an opening for adjacent prosthetic devices and rehabilitation hardware, an area where venture money is flooding into neural prosthetics.

Reporting based on coverage from MIT Technology Review, Scientific American, South China Morning Post and People's Daily Online.

Category: Prosthetics

Tags: Medical Devices Medical Robotics Prosthetics Brain-Computer Interface China

Related Articles